Compare Hormel Foods Corp (HRL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Recursion Pharmaceuticals Inc — how do they compare? Hormel Foods Corp trades at $19.48 (market cap $10.69B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Hormel Foods Corp is far larger — about 5× Recursion Pharmaceuticals Inc's market cap, and Hormel Foods Corp pays a 6.02% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HRL | RXRX | |
|---|---|---|
Market Cap | $10.69B | $2.14B |
Volume | 10,041,387 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $6.79 |
52-Week Low | $19.42 | $2.84 |
Typical Hold Time | 99 Days | 22 Days |
Enterprise Value | $12.67B | $1.66B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.55, down 1.66% on the day, with a bearish technical signal from moving averages. The company reported a net income margin of 2.82% for 2025, with recent quarterly EPS beats but a year-over-year decline in net income. Its acquisition of Brakebush for $1.06 billion aims to expand its foodservice chicken business, while the dividend yield remains a key attraction as a Dividend King.
The stock presents a mixed outlook: analyst consensus targets $24.25 imply upside, but high P/E of 31.53 and shrinking profit margins pose valuation and growth concerns. Risks include execution on acquisitions and consumer spending pressures, yet the strong dividend history offers income stability.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
